The effect of oral metformin on insulin sensitivity in insulin-resistant ponies.

The study focuses on the impact of a glucose-lowering drug, metformin, on insulin sensitivity in ponies known to have insulin resistance. However, the research found no significant changes across key indicators such as insulin sensitivity, glucose effectiveness, and insulin response to glucose after treatment with metformin.

Explanation of the Research Paper

• The study aimed to discover whether metformin, a drug widely used to manage human diabetes by boosting the tissues’ insulin sensitivity, could function similarly in insulin-resistant ponies. The question arose because metformin is believed to enhance insulin sensitivity without prompting insulin secretion in humans.
• With a cross-over design study, six insulin-resistant ponies underwent a frequently-sampled intravenous glucose tolerance test (FSIGT) – a test to measure how quickly glucose is cleared from the blood. This procedure ran the Minimal Model analysis, an acknowledged method to yield data on insulin dynamics and glucose tolerance.
• In the experiment, the ponies were split into two groups: one group was given metformin orally at a dosage of 15mg/kg bodyweight (BW) twice a day for 21 days, and the other, the control group, was given a placebo.
• The study measured indices for insulin sensitivity (SI), glucose effectiveness (Sg), acute insulin response to glucose (AIRg), and the disposition index (DI). It also evaluated the body condition score (BCS), BW, and cresty neck score (CNS) – one of the physical indicators of insulin resistance. However, no significant changes or improvements were noted in any of these variables, indicating that metformin had no measurable effect on the ponies’ insulin sensitivity.
• The lack of effect from metformin could be due to its poor bioavailability in horses, as was suggested in other recent studies. Bioavailability refers to the amount of a drug that actually enters the bloodstream when introduced into the body and has an active effect. If metformin’s bioavailability is low in horses, the chronic doses given to the ponies might not have reached a therapeutic level. Alternatively, metformin may only show beneficial effects in obese ponies undergoing weight loss or in instances of high blood sugar levels.